Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
Featured trial
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects

  • 5 views
  • 24 Jun, 2021
  • 1 location
None
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone

This research study is a multicentre prospective pharmacokinetic study. The clinical and biological data will be collected in the framework of a prospective study. The drug to be evaluated is a glucocorticoid routinely used to treat Systemic lupus erythematosus (SLE) patient. Initial dose of prednisone must be oral and at …

immunosuppressive agents
corticosteroids
mycophenolate
rituximab
prednisone
  • 8 views
  • 29 Sep, 2021
  • 1 location
None
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different COVID-19 vaccine booster doses in participants with autoimmune disease requiring immunosuppressive medications. All study participants will have negative serologic or sub-optimal responses (defined as a Roche Elecsys Anti-SARS-CoV-2 S (RBD) result 50 U/mL) to initial …

SARS
hydroxychloroquine
lupus
progressive systemic sclerosis
rheumatism
  • 11 views
  • 22 Oct, 2021
  • 10 locations
None
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

HSCT has been implemented in (inter)national treatment guidelines for diffuse cutaneous systemic sclerosis (dcSSc) and is offered in clinical care and reimbursed by national health insurance in several European countries. However, data and specific guidelines on the best timing of HSCT in the course of dcSSc are lacking. In particular, …

  • 0 views
  • 18 Apr, 2021
  • 14 locations
None
Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

Tacrolimus is the standard immunosuppressive drug used to prevent organ rejection post liver transplant. One side effect of Tacrolimus is nephrotoxicity. Everolimus does not have the nephrotoxicity side effects of Tacrolimus. Replacement of Tacrolimus by Everolimus may have a reduced incidence of renal dysfunction in liver transplant patients who already …

glomerular filtration rate
mycophenolate mofetil
hypertension
hepatitis c
acute renal failure
  • 1 views
  • 24 Jan, 2021
  • 1 location
None
Once Daily Immunosuppression Regimen

The purpose of this research study is to determine whether an immunosuppressive maintenance regimen of Envarsus/azathioprine compared to a tacrolimus/ mycophenolic acid regimen is associated

kidney transplant
azathioprine
thymoglobulin
envarsus xr
tacrolimus
  • 6 views
  • 17 Feb, 2021
  • 1 location
None
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

acute rejection, graft and patient survival as compared to a combination of twice-daily immediate release tacrolimus and mycophenolate mofetil/mycophenolic acid.

  • 0 views
  • 08 Mar, 2021
  • 1 location
None
A Research Study To See How Well an Eye Drop SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) Works and What Side Effects There Are in Subjects With Dry Eye Disease

> The purpose of this research study is to see how well SURF-100 works to treat dry eye and what potential side effects there are, and to compare it with Vehicle (placebo), 0.1% mycophenolic acid

  • 1 views
  • 24 May, 2021
  • 40 locations
None
Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation

with anti-CD25 monoclonal anti-body (basiliximab), mycophenolic acid (MPA), and mammalian target of rapamycin (mTOR) - inhibition with everolimus to determine its safety and to investigate

prednisolone
mycophenolic acid
myfortic
immunosuppressive agents
immunosuppression
  • 10 views
  • 07 Nov, 2020
  • 1 location
None
Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome

Phase II, randomized controlled, unblinded clinical trial. Will evaluate whether the administration of oral cyclosporine started on day 0 of transplantation is effective in reducing the incidence of cytokine release syndrome (CRS) in patients who receive an outpatient haploidentical transplant.

  • 0 views
  • 11 Mar, 2021
  • 1 location